Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUNICANCER
About this trial
This database compiles data from existing data available from patient's electronic medical records (EMR) at the 38 participating hospitals (20 French comprehensive cancer centers and 18 public hospitals).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult (over 18)
Treated (with radiotherapy or systemic anti-cancer treatment) for a lung cancer or diagnosed with metastatic lung cancer over the selection period at one of the participating site
Disqualifiers
None
Trial population
All consecutive patients treated for lung cancer at one of the 38 French participating sites (Private comprehensive cancer centers and public hospitals).
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Patient characteristics
Age in years, Tobacco consumption, other exposures, Legal recognition as occupational disease, Medical history, History of other cancer, weight in kg and performance status (ECOG)
Time frame
Baseline2
Tumor characteristics
Staging, Tumor size, sampling Method, histological type
Time frame
Baseline3
Treatment patterns
Drug, therapeutic class, treatment duration at each n treatment line
Time frame
From Baseline until 2024 (yearly basis)Secondary outcomes
1
Median overall survival
Assessment of overall survival through treatment lines
Time frame
From date of diagnosis or first treatment until the date of death from any cause. Follow up until 20242
Median surrogate endpoints for overall survival
Surrogate endpoints (Progression-free Survival, Time to Progression, Time to Next Treatment) at each n treatment line.
Time frame
From start date of the nth treatment line until the date of first applicable event. Follow up until 2024Sponsors and contacts
Click on the lead sponsor to view all of their trials.
UNICANCER
Lead sponsor
AstraZeneca
Collaborator
Merck Sharp & Dohme LLC
Collaborator
Roche Pharma AG
Collaborator
Pfizer
Collaborator
Bristol-Myers Squibb
Collaborator
Janssen, LP
Collaborator
Amgen
Collaborator
Daiichi Sankyo
Collaborator
Pierre Fabre Medicament
Collaborator
Boehringer Ingelheim
Collaborator
Source ClinicalTrials.gov